A concerning message has begun circulating within parts of the regenerative medicine community: that blood clots formed during an EBO2 procedure are proof that the treatment is “cleaning” the patient’s blood.
Dramatic images of material collected from an extracorporeal circuit may attract attention online, but they should never replace accurate clinical education. Clots that develop within an EBO2 circuit are not toxins, arterial plaque, oils, or harmful debris pulled from the patient’s bloodstream. They are evidence that blood coagulated after entering the extracorporeal system.
For clinics offering EBO2, understanding this distinction is essential for patient safety, proper training, and informed consent.
Why Anticoagulation Is Essential During EBO2
Extracorporeal Blood Oxygenation and Ozonation, commonly referred to as EBO2 or EBOO, is a procedure in which blood circulates outside the body through a specialized system before being returned to the patient.
Whenever blood encounters artificial surfaces, including tubing, connectors, and filtration components, the body’s coagulation system may be activated. This is not unique to EBO2. It is a fundamental consideration in extracorporeal procedures.
Anticoagulation is therefore used to help prevent blood from clotting within the circuit. The appropriate anticoagulation strategy must be established and supervised by a qualified physician based on the patient, the equipment, applicable protocols, and clinical circumstances.
The International Scientific Committee of Ozone Therapy’s published EBOO procedure, for example, includes priming the contactor and blood lines with a heparin solution. It also identifies signs of thrombosis, such as a clogged return-line filter, as conditions requiring corrective action rather than desired treatment outcomes. [ISCO3 EBOO Standard Operating Procedure]
What Clot Formation Actually Means
When a clot forms inside an EBO2 circuit, it was not necessarily circulating through the patient’s body in that form before treatment. Blood can coagulate after it has been removed from the body and exposed to the circuit if anticoagulation is insufficient or the system is not appropriately monitored.
That means visible clotting should not be described as:
- Toxins removed from the blood
- Arterial plaque extracted from the body
- “Oil” or fat filtered from the bloodstream
- Proof that the procedure worked
- A desirable therapeutic endpoint
Instead, clotting within the circuit should prompt the clinical team to assess the procedure and respond according to its physician-directed protocols.
Why Presenting Clots as a Benefit Is Problematic
Calling a procedure-generated clot “what was hiding in the patient’s blood” creates an inaccurate impression of both the patient’s health and the treatment’s mechanism.
It may also interfere with informed consent. Patients deserve to understand what is happening during a procedure, including the difference between material intentionally processed by the system and a complication that develops inside the circuit.
When clotting is promoted as a successful outcome, it may unintentionally encourage poor practices by making inadequate anticoagulation appear desirable. In any extracorporeal procedure, the goal should be consistent execution, continuous observation, and an appropriate clinical response to abnormalities.
EBO2 Requires More Than the Right Equipment
A well-designed system is only one part of delivering EBO2 responsibly. Clinics must also have:
- Properly trained physicians and clinical personnel
- Clear patient screening and informed-consent procedures
- Physician-directed anticoagulation protocols
- Continuous monitoring throughout treatment
- Established procedures for identifying and managing complications
- Accurate, responsible patient education and marketing
Anticoagulation is not a one-size-fits-all calculation. It must account for factors such as the patient’s medical history, medications, coagulation status, treatment duration, and clinical response. Clinics should follow the instructions for their specific system, applicable laws and regulations, and protocols established by their medical leadership.
Protecting the Credibility of EBO2
Advanced medical technologies earn credibility through careful training, transparent communication, and adherence to sound clinical standards, not through attention-grabbing imagery.
At PURXCELL, we believe clinics offering EBO2 have a responsibility to distinguish legitimate treatment processes from procedural complications. Blood clot formation within an extracorporeal circuit should be recognized, evaluated, and addressed. It should never be repackaged as evidence of toxins or plaque being removed from a patient’s body.
Patients and providers deserve better than dramatic but misleading explanations. They deserve properly trained teams, accurately represented procedures, and systems supported by a commitment to safety and clinical integrity.
This article is intended for general professional education and does not provide patient-specific medical advice or replace a clinic’s physician-directed protocols, device instructions, or applicable regulatory requirements.
